Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma
Authors:
- Ronald J. SchmittRSRonald J. Schmitt
- Sarah M. KreidlerSKSarah M. Kreidler
- Deborah H. GlueckDGDeborah H. Glueck
- Rodabe N. AmariaRARodabe N. Amaria
- Rene GonzalezRGRene Gonzalez
- Karl LewisKLKarl Lewis
- Brian M. BagroskyBBBrian M. Bagrosky
- Jennifer J. KwakJKJennifer J. Kwak
- Phillip J. KooPKPhillip J. Koo
- 1 February 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 37 (2) , 122-128
Abstract
Purpose Metabolic response to treatment measured by fluorine-18 fluorodeoxyglucose (18F-FDG) PET has prognostic implications in many cancers. This study investigated the association between survival and early changes on 18F-FDG PET/computed tomography (CT) for patients with BRAF-mutant melanoma receiving combined BRAF and MEK inhibition therapy. Materials and methods Overall, 24 patients with advanced BRAF-mutant melanoma were included. Patients were treated with a BRAF inhibitor (vemurafenib or dabrafenib) and a MEK inhibitor (cobimetinib or trametinib), and were imaged at baseline and shortly thereafter with 18F-FDG PET/CT. Each scan yielded two values of maximum standardized uptake value (SUVmax): one for the most metabolically active focus and one for the least responsive focus. Short-term treatment response was assessed by evaluating the target lesions using the EROTC criteria. A Cox proportional hazards model was used to examine associations between overall survival (OS) and progression-free survival (PFS) and changes in SUVmax. Results The mean time to follow-up 18F-FDG PET/CT was 26 days. At follow-up, two patients achieved a complete response. For the most metabolically active focus, 22 patients showed a partial response. For the least responsive focus, 18 patients showed a partial response, two had stable disease, and two had progressive disease. A total of 16 patients were alive at the end of the study. For the most metabolically active tumor, no association was observed between changes in SUVmax and OS (P=0.73) or PFS (P=0.17). For the least responsive tumor, change in SUVmax was associated with PFS [hazard ratio (HR)=1.34, 95% confidence interval (CI): 1.06–1.71, P=0.01], but not OS (P=0.52). The ECOG score was associated with OS (HR=11.81, 95% CI: 1.42–97.60, P=0.02) and PFS (HR=24.72, 95% CI: 3.23–189.42, P=0.002). Conclusion Change in SUVmax for the least responsive tumor and baseline functional performance may be useful prognostic indicators for PFS in patients with BRAF-mutant melanoma.Keywords
This publication has 27 references indexed in Scilit:
- [18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging in Oncology: Initial Staging and Evaluation of Cancer TherapyMedical Principles and Practice, 2013
- FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973EJNMMI Research, 2012
- Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PETJournal of Nuclear Medicine, 2011
- 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor ErlotinibJournal of Nuclear Medicine, 2011
- Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapyBMC Cancer, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Response assessment by combined PET–CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapyAnnals of Oncology, 2010
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal of Cancer, 1999
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958